<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00706771</url>
  </required_header>
  <id_info>
    <org_study_id>TNH 18/08</org_study_id>
    <nct_id>NCT00706771</nct_id>
  </id_info>
  <brief_title>Bicarbonate and Lipocalin in Systemic Inflammatory Response Syndrome (SIRS) Study</brief_title>
  <acronym>BLISS</acronym>
  <official_title>A Randomized Double-blind Controlled Pilot Feasibility and Safety Trial of NGAL-directed Sodium Bicarbonate to Protect Renal Function in Patients With the Systemic Inflammatory Response Syndrome, Oliguria and Elevated Lipocalin Levels</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Austin Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Austin Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will determine the feasibility, safety and efficacy of intravenous sodium
      bicarbonate in reducing progression to overt acute renal failure in patients with the
      systemic inflammatory response syndrome, and low urine output or early acute renal impairment
      as defined by serum neutrophil gelatinase-associated lipocalin (NGAL).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators hypothesise:

        1. In patients with SIRS and oliguria the early administration of sodium bicarbonate or
           sodium chloride (control) triggered by an abnormally high NGAL level is feasible.

        2. In patients with SIRS and oliguria the early administration of sodium bicarbonate or
           sodium chloride (control) triggered by an abnormally high NGAL level is safe.

        3. In patients with SIRS and oliguria the early administration of sodium bicarbonate or
           sodium chloride (control) triggered by an abnormally high NGAL level leads to signs or
           trends of efficacy as measured by serum creatinine derived indices.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The ability to deliver the study protocol safely and rapidly with a trend to improved renal outcomes</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Attenuation in lipocalin levels</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease in the magnitude in serum creatinine rise</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ability to deliver the study protocol without significant biochemical side effects</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Systemic Inflammatory Response Syndrome</condition>
  <condition>Oliguria</condition>
  <condition>Renal Impairment</condition>
  <arm_group>
    <arm_group_label>Sodium bicarbonate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>sodium bicarbonate: loading of 0.5 mmol/kg and the continuous infusion o f0.2 mmol/kg/hr</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sodium chloride</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>sodium chloride: loading of 0.5 mmol/kg and the continuous infusion o f0.2 mmol/kg/hr</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium bicarbonate</intervention_name>
    <description>Sodium bicarbonate: loading dose of 0.5 mmol/Kg and then continuous infusion of 0.2 mmol/Kg/hr</description>
    <arm_group_label>Sodium bicarbonate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium chloride</intervention_name>
    <description>0.9% sodium chloride: loading dose of 0.5 mmol/Kg and then continuous infusion of 0.2 mmol/Kg/hr</description>
    <arm_group_label>Sodium chloride</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Consent obtained

          -  Diagnosis of SIRS. Requires any TWO of:

        temperature &gt; 38°C or &lt; 36°C OR heart rate &gt; 90 beats/min OR respiratory rate &gt; 20
        breaths/min. PaCO2 &lt; 32 mm Hg OR alteration of white blood cell count &gt; 12,000 cells/mm3, &lt;
        4,000 cells/mm3, or the presence of &gt; 10% immature neutrophils

          -  elevated lipocalin level

          -  Arterial line already in place

          -  Central venous catheter already in place

          -  Age ≥ 18 years

          -  Within 24 hours of admission to the ICU

        Exclusion Criteria:

          -  Unlikely to remain in ICU for &gt;72 hours

          -  Moribund patient

          -  Pre-existing CKD, transplant or ESRD

          -  Receiving (or about to receive) continuous renal replacement therapy for acute renal
             failure at time of enrolment

          -  Diagnosis of acute GN, AIN, vasculitis or post-renal aetiology

          -  Known/suspected study allergy to sodium bicarbonate

          -  Enrolling physician concern about patient enrolment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael C Reade, MBBS DPhil</last_name>
    <role>Principal Investigator</role>
    <affiliation>Austin &amp; Northern Hospitals, University of Melbourne</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nerina Harley, MBBS FCICM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Melbourne Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rinaldo Bellomo, MD FJFICM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Austin Hospital, University of Melbourne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Austin Hospital</name>
      <address>
        <city>Heidelberg, Melbourne</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3154</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 26, 2008</study_first_submitted>
  <study_first_submitted_qc>June 27, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2008</study_first_posted>
  <last_update_submitted>June 26, 2014</last_update_submitted>
  <last_update_submitted_qc>June 26, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 30, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Austin Health</investigator_affiliation>
    <investigator_full_name>Rinaldo Bellomo</investigator_full_name>
    <investigator_title>Director of Intensive Care Research</investigator_title>
  </responsible_party>
  <keyword>sodium bicarbonate</keyword>
  <keyword>serum neutrophil gelatinase associated lipocalin</keyword>
  <keyword>renal impairment</keyword>
  <keyword>renal failure</keyword>
  <keyword>systemic inflammatory response syndrome</keyword>
  <keyword>defined</keyword>
  <keyword>by serum NGAL ≥ 100 ng/ml.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Systemic Inflammatory Response Syndrome</mesh_term>
    <mesh_term>Oliguria</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

